Update on the use of trilostane in dogs

Julie Denise Lemetayer, Shauna Blois

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Many articles published in the past few years have contributed to a better understanding of the use of trilostane in dogs. Trilostane is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, the enzyme essential for synthesis of Cortisol and all other steroids. Trilostane is reported to be safe and effective in the treatment of pituitary-dependent hyperadrenocorticism (HAC), adrenal-dependent HAC, and alopecia X. While trilostane controls most of the clinical signs associated with HAC, abnormalities such as hypertension, hypercoagulability, and proteinuria may persist despite therapy. Because the duration of Cortisol suppression after a dose of trilostane is often less than 12 hours, many dogs with HAC could benefit from low dose trilostane treatment every 12 hours. Many controversies regarding trilostane still exist. This review provides a comprehensive commentary on trilostanes indications, mode of action, dose, monitoring, efficacy, and adverse effects.

Original languageEnglish (US)
Pages (from-to)397-407
Number of pages11
JournalCanadian Veterinary Journal
Volume59
Issue number4
StatePublished - Apr 1 2018
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Lemetayer, J. D., & Blois, S. (2018). Update on the use of trilostane in dogs. Canadian Veterinary Journal, 59(4), 397-407.